• 1. An approach for correlating the structural and electrical properties of Zr4+-modified SrBi4Ti4O15/SBT ceramic
  Priyambada Nayak,Tanmaya Badapanda,Anil Kumar Singh,Simanchalo Panigrahi RSC Adv., 2017,7, 16319-16331
• 2. An aptamer-based keypad lock system?
  Yaqing Liu,Jiangtao Ren,Jing Li,Jiyang Liu,Erkang Wang Chem. Commun., 2012,48, 802-804
• 3. An Assessment of the Laminar Hypersonic Double-Cone Experiments in the LENS-XX Tunnel
  JaideepRay,PatrickBlonigan,EricT.Phipps,KathrynMaupin
• 4. An atomically efficient, highly stable and redox active Ce0.5Tb0.5Ox (3% mol.)/MgO catalyst for total oxidation of methane?
  Juan J. Sánchez,Miguel López-Haro,Juan C. Hernández-Garrido,Ginesa Blanco,Miguel A. Cauqui,José M. Rodríguez-Izquierdo,José A. Pérez-Omil,José J. Calvino,María P. Yeste J. Mater. Chem. A, 2019,7, 8993-9003
• 5. Alt-proteins: A promising future

• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Fatty Acyls Fatty acids and conjugates Long-chain fatty acids
• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Fatty Acyls Long-chain fatty acids

Pinane Thromboxane A2 (PTA2) - A Comprehensive Overview

Pinane Thromboxane A2 (PTA2), also known by its CAS number 71111-01-8, is a bioactive compound that has garnered significant attention in the fields of pharmacology and biotechnology. This compound is derived from the structural modification of thromboxane A2, a potent vasoconstrictor and platelet aggregator. The incorporation of the pinane moiety into its structure has been shown to enhance its pharmacokinetic properties, making it a promising candidate for therapeutic applications.

The synthesis of PTA2 involves a multi-step process that includes the isolation of thromboxane A2 from natural sources, followed by chemical modification to introduce the pinane group. This process ensures that the compound retains its biological activity while improving its stability and bioavailability. Recent studies have demonstrated that PTA2 exhibits potent anti-inflammatory and anti-thrombotic effects, which are critical for treating conditions such as cardiovascular diseases and inflammatory disorders.

In terms of mechanism of action, PTA2 primarily interacts with the thromboxane receptor (TP), which is expressed in various tissues, including the vasculature and immune cells. Activation of this receptor leads to downstream signaling pathways that regulate vasoconstriction, platelet aggregation, and inflammation. However, due to its modified structure, PTA2 shows selectivity towards certain isoforms of the TP receptor, reducing off-target effects and improving its therapeutic index.

Recent advancements in computational chemistry have enabled researchers to perform detailed molecular docking studies on PTA2. These studies have provided insights into the binding affinity of PTA2 with various receptors and enzymes, paving the way for the development of more potent analogs. For instance, a study published in 2023 highlighted the potential of PTA2-based therapies in managing chronic inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease.

In addition to its pharmacological applications, PTA2 has also been explored for its potential in diagnostic imaging. Researchers have developed radiolabeled derivatives of PTA2 that can be used to visualize TP receptor expression in vivo. This approach has shown promise in early-stage diagnosis of cardiovascular diseases, where TP receptor expression is often upregulated.

The safety profile of PTA2 has been extensively evaluated in preclinical models. Studies indicate that it exhibits low toxicity at therapeutic doses, with no significant adverse effects on major organ systems. However, further clinical trials are required to confirm these findings and establish its safety profile in humans.

In conclusion, Pinane Thromboxane A2 (PTA2), with its CAS number 71111-01-8, represents a novel class of bioactive compounds with potential applications in treating a wide range of diseases. Its unique structure, combined with advancements in synthetic chemistry and molecular biology, positions it as a leading candidate for future therapeutic interventions. As research continues to uncover new insights into its mechanisms and applications, the prospects for PTA2-based therapies remain highly promising.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)